Jun 22, 2026 04:05PM
Jun 22, 2026 06:59AM
Jun 17, 2026 08:45AM
Jun 17, 2026 08:45AM
Jun 5, 2026 07:00AM
Jun 4, 2026 07:00AM
Jun 2, 2026 07:00AM Ocular Therapeutix™ to Host Investor Day on June 17, 2026
May 15, 2026 07:00AM
May 8, 2026 04:05PM
May 5, 2026 07:00AM
Apr 29, 2026 07:00AM
Apr 29, 2026 07:00AM
Apr 28, 2026 07:00AM
Apr 27, 2026 07:00AM Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences
Apr 22, 2026 07:00AM
Apr 19, 2026 10:00AM
Apr 14, 2026 07:00AM
Apr 13, 2026 07:01AM
Apr 13, 2026 07:00AM
Apr 1, 2026 07:00AM
Mar 9, 2026 04:01PM Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 24, 2026 07:00AM
Feb 23, 2026 07:00AM
Feb 20, 2026 07:53AM
Feb 19, 2026 02:01PM
Feb 17, 2026 07:02AM
Feb 17, 2026 07:00AM
Feb 13, 2026 05:00PM Ocular Therapeutix to announce SOL-1 phase 3 trial results for wet AMD
Feb 13, 2026 05:00PM
Feb 6, 2026 04:01PM
Feb 5, 2026 08:55AM
Feb 5, 2026 07:00AM
Jan 23, 2026 04:01PM
Jan 21, 2026 07:00AM
Jan 21, 2026 07:00AM Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer
Dec 9, 2025 04:00AM
Dec 8, 2025 07:02AM
Dec 8, 2025 07:00AM
Dec 8, 2025 06:46AM
Dec 8, 2025 05:08AM
Dec 8, 2025 04:34AM
Dec 5, 2025 07:00AM Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 24, 2025 07:00AM
Nov 24, 2025 07:00AM
Nov 12, 2025 07:00AM
Nov 7, 2025 07:00AM
Nov 4, 2025 07:05AM
Nov 4, 2025 07:02AM
Nov 4, 2025 07:00AM Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R
Oct 28, 2025 07:00AM

323,778 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All